Department of Child and Adolescent Psychiatry, University of Cologne, Robert-Koch-Str. 10, 50931, Cologne, Germany.
Eur Child Adolesc Psychiatry. 2011 Oct;20 Suppl 2(Suppl 2):S297-307. doi: 10.1007/s00787-011-0207-z.
Satisfaction with medication is important in the evaluation of overall treatment outcome. There is a lack of consistent and validated rating scales for satisfaction with medication in ADHD, therefore comparison across studies is difficult. Here, we analyse the psychometric properties of the satisfaction with medication scale (SAMS), a new item-based questionnaire that assesses satisfaction with ADHD medication. Furthermore, we evaluate the predictive effect of ADHD symptoms and quality of life (QoL) on satisfaction. Data on satisfaction with Equasym XL(®) (methylphenidate) were collected in the OBSEER study using the parent (SAMS-P, n = 589) and patient (SAMS-S, n = 552) versions of the SAMS questionnaire. Internal consistency, item-total and cross-informant correlations, and the stability of satisfaction ratings over time were assessed. Satisfaction with medication scores were then correlated with ratings of ADHD symptoms and QoL. Rates of overall satisfaction with Equasym XL(®) among parents and children were high (>70%), as was internal consistency for both SAMS-P and SAMS-S (Cronbach's alpha > 0.9). Similarly, item-total correlations were high (r = 0.71-0.90) for SAMS-P and medium-high (r = 0.57-0.77) for SAMS-S. Cross-informant correlations and the stability of satisfaction ratings were moderate (r = 0.54-0.59 and 0.48-0.60, respectively). ADHD symptom and QoL ratings were significantly negative and positive predictors of satisfaction, explaining 36-52% of satisfaction variance at the final visit. The results show that parent and patient satisfaction was high and could be assessed reliably with the new SAMS questionnaire. Parent and patient ratings were moderately correlated, and symptom severity, functional impairment and QoL were the most significant predictors of satisfaction.
对药物的满意度在评估整体治疗效果中很重要。目前 ADHD 患者对药物的满意度缺乏一致且经过验证的评估量表,因此很难进行跨研究比较。在这里,我们分析了新的基于项目的药物满意度量表(SAMS)的心理测量特性,该量表评估了 ADHD 药物的满意度。此外,我们还评估了 ADHD 症状和生活质量(QoL)对满意度的预测作用。使用 SAMS 问卷的家长(SAMS-P,n = 589)和患者(SAMS-S,n = 552)版本,在 OBSEER 研究中收集了关于 Equasym XL(®)(哌甲酯)的满意度数据。评估了内部一致性、项目总分和交叉信息源相关性以及随时间变化满意度评分的稳定性。然后将药物满意度评分与 ADHD 症状和 QoL 的评分相关联。父母和孩子对 Equasym XL(®)的总体满意度较高(>70%),SAMS-P 和 SAMS-S 的内部一致性也很高(Cronbach's alpha > 0.9)。同样,SAMS-P 的项目总分相关性较高(r = 0.71-0.90),SAMS-S 的中等偏高(r = 0.57-0.77)。交叉信息源相关性和满意度评分的稳定性适中(r = 0.54-0.59 和 0.48-0.60)。ADHD 症状和 QoL 评分与满意度呈显著负相关和正相关,在最后一次就诊时解释了满意度变异的 36-52%。结果表明,家长和患者的满意度很高,新的 SAMS 问卷可以可靠地评估满意度。家长和患者的评分中度相关,症状严重程度、功能障碍和 QoL 是满意度的最重要预测因素。